We applied the probabilistic definition of Bliss independence to evaluate time-dependent changes in the efficacies of a group of 12 compounds in sequential combination with BRAF kinase inhibitor, Vemurafenib, plus MEK kinase inhibitor, Trametinib, in two BRAF-mutated melanoma cell lines COLO858 and MMACSF over the course of five days (see Methods for details). Here, BRAF is linked to melanoma.